Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are considering adipose-derived stem cell therapy in Japan as an international patient, the most useful step you can take is to prepare for your first consultation. This is a self-pay (non-insured) regenerative treatment, and whether it is appropriate for you can only be judged by a physician after an examination. This article outlines the questions worth bringing to a first conversation with Grand Green Osaka Umekita Clinic in Osaka (Umeda), so that you can decide with a clear picture rather than a marketing impression.
Start with what the treatment actually is
At Grand Green Osaka Umekita Clinic, the treatment uses mesenchymal stem cells taken from your own fat tissue. A very small amount of fat, about the size of a few grains of rice, is collected under local anesthesia. The cells are then cultured and expanded at a specialized facility and returned to your body by intravenous infusion. Both the collection and the infusion are done on an outpatient basis, without hospitalization.
Mesenchymal stem cells have been reported in research to secrete anti-inflammatory substances and growth factors that may support the repair of damaged tissue. However, research results vary between studies and between conditions, and these findings should not be read as a promise of any particular outcome for an individual. A good first question is simply: what does the evidence say about my specific condition, and how strong is it?
Questions about suitability and your medical history
Not everyone is a candidate for regenerative medicine, and the decision rests with the treating doctor. Before your consultation, it helps to gather information that the physician will almost certainly want to review. Consider preparing the following:
- A summary of your diagnosis, including imaging reports or test results from your home country, ideally with an English or Japanese translation if available
- A list of current medications and supplements, and any history of allergies, especially to local anesthetics
- Past surgeries, ongoing treatments, and any conditions such as infections, autoimmune disease, or a history of cancer
- The standard treatments you have already tried, and what your current doctors have recommended
It is reasonable to ask the physician directly whether stem cell therapy is suitable for you, whether it should be considered alongside standard care, and whether any of your conditions would make it inadvisable. Stem cell therapy should not be seen as a replacement for standard medical treatment, and a responsible clinic will discuss it as one option among others.
Understanding the legal framework in Japan
In Japan, regenerative medicine is provided under the Act on the Safety of Regenerative Medicine. Clinics must have a provision plan reviewed by a certified committee and submit it to the authorities before offering a treatment, and cell culture is carried out at facilities that meet national requirements. Because it is not covered by Japan’s public health insurance, the treatment is self-pay.
For an international patient, this means you can reasonably ask the clinic to explain which provision plan covers the treatment, how the cells are processed, and how your information is handled. You may also wish to check whether the treatment you are being offered is the same one described on the clinic’s official information page. Clear answers to these questions are a sign of a transparent practice, although they do not by themselves indicate how well the treatment will work for you.
Discussing risks, side effects, and costs openly
Every medical procedure carries risk. Fat collection under local anesthesia can involve bruising, discomfort, or infection at the collection site, and intravenous infusion of cells can be associated with reactions such as fever or allergic symptoms. Because the cells come from your own body, the risk of rejection is considered lower than with donor cells, but a lower risk is not the same as no risk. The physician should explain what side effects are possible, how they are monitored, and what happens if one occurs.
Cost is another point to confirm in writing before you decide. Fees for self-pay treatment are set by each clinic, so ask what is included, such as consultation, tests, fat collection, cell culture, each infusion, and follow-up, and whether any items are charged separately. Please refer to the clinic’s fee page and confirm the current details with the staff rather than relying on figures found elsewhere online.
Planning your trip and follow-up from abroad
Because the cells are cultured between the collection and the infusion, treatment generally involves more than one visit. If you live outside Japan, ask how the schedule is arranged, how long you would need to stay in Osaka, and what the timeline might look like for you personally. These details depend on your medical situation and the doctor’s plan, so they are best confirmed during your consultation.
It is also worth asking how follow-up will work once you are back home. For example, you may want to know whether you can send updates, how to reach the clinic if you have a concern, and how to share records with your regular doctor. Communication in your own language matters here. The clinic provides an information page for international patients, and you can ask in advance which languages are available for consultation and for consent documents.
A short checklist for your first consultation
To make the most of your appointment, you might bring a simple list of questions. The following points cover the main areas discussed above:
- Is this treatment suitable for my condition, and what is the supporting evidence?
- How does it fit with the standard treatments I am already receiving?
- What are the possible risks and side effects, and how are they handled?
- What is the full cost, and what is included?
- How many visits are needed, and how long should I stay in Osaka?
- How will follow-up be handled after I return home?
Adipose-derived stem cell therapy is a self-pay regenerative treatment offered under Japan’s regenerative medicine regulations, and its suitability, risks, side effects, and costs must be confirmed through a medical examination and consultation with a doctor. If you are considering a visit to Osaka, we encourage you to review the clinic’s treatment and fee pages and to contact the team with your questions before making any decision.
- Ask about suitabilityDoctor decides after examination
- Know Japan's rulesRegenerative medicine law
- Confirm risksSide effects explained
- Check self-pay costsWhat is included
This figure is a conceptual summary of the article's content
References
- PubMed: Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). (2017)
- PubMed: Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study. (2024)
- PubMed: Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. (2022)
- PubMed: Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). (2023)
- PubMed: Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. (2025)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- PMC: Functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells: a case report. (2023)
- PMC: Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients. (2020)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.